10-Q: Myomo Reports Q2 2026 Revenue Growth, Margin Improvement

Myomo, Inc. announced its second quarter 2026 financial results, showcasing a 21% increase in revenue and a significant improvement in gross margins, though net losses persist.

Summary

• Myomo, Inc. reported Q2 2026 revenue of $11.7 million, a 21% increase year-over-year, and for the six months ended June 30, 2026, revenue was $21.8 million, up 12%.
• Gross profit for the quarter increased by 39% to $8.4 million, with gross margin improving to 72.1% from 62.7% in the prior year period.
• Net loss for the quarter was $4.0 million, compared to $4.6 million in Q2 2025. For the six months, the net loss was $7.0 million, an improvement from $8.1 million in the prior year.
• The company ended the quarter with $11.2 million in cash and cash equivalents and $2.2 million in short-term investments.
• A significant factor impacting net loss was the change in fair value of derivative liabilities, which resulted in a $1.2 million expense in the quarter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with revenue growth and improved gross margins offset by continued net losses and significant derivative liability fluctuations.

Positives

• Revenue increased by 21% to $11.7 million for the three months ended June 30, 2026, and by 12% to $21.8 million for the six months ended June 30, 2026.
• Gross margin improved significantly to 72.1% for the three months ended June 30, 2026, from 62.7% in the prior year period.
• Operating expenses for R&D decreased by 14% and 12% for the three and six months ended June 30, 2026, respectively.
• The company has a cash balance of $11.2 million and short-term investments of $2.2 million as of June 30, 2026, which management believes is sufficient for at least the next twelve months.
• The company is focusing on growing revenues from recurring sources like the MyoConnect program and O&P channel to reduce reliance on advertising.

Negatives

• The company incurred a net loss of $4.0 million for the three months ended June 30, 2026, and $7.0 million for the six months ended June 30, 2026.
• The change in fair value of derivative liabilities resulted in a significant expense of $1.2 million for the quarter and $360,662 for the six months.
• Cash used in operating activities was $4.1 million for the six months ended June 30, 2026.
• The company has an accumulated deficit of $125.7 million as of June 30, 2026.
• The China joint venture with Ryzur Medical has been terminated due to Ryzur Medical filing for bankruptcy.

Risks

• Dependence on third-party payers for reimbursement, including Medicare Part B and Medicare Advantage plans, which represent a significant portion of revenue.
• The company's ability to achieve or obtain sufficient reimbursement from third-party payers for its products.
• Dependence upon external sources for financing operations and the ability to scale the business to return to positive cash flow.
• Potential supply chain disruptions impacting the ability to deliver and fit custom-fabricated devices.
• The company's ability to effectively execute its business plan and scale up operations.
• Risks associated with international operations, including currency exchange rate fluctuations, economic weakness, and political instability.
• The company's ability to manage its growth effectively, particularly in the O&P channel and international markets.
• The valuation of derivative liabilities, which are subject to significant unobservable inputs and can cause material fluctuations in reported results.

Future Outlook

The company anticipates continued revenue growth in 2026, driven by investments in recurring revenue sources like the MyoConnect program and O&P channels, aiming to reduce dependence on advertising and minimize fixed expense growth. Management believes current cash, cash equivalents, and short-term investments are sufficient for at least the next twelve months.

Management Comments

• Management's operating plans are primarily focused on growing revenues from recurring sources, including expanding its MyoConnect program to generate referrals in rehab clinics and stroke centers around the country, continued growth in revenues in the O&P channel, as well as International operations, while reducing the cost of patient acquisition and minimizing the growth in fixed expenses.
• The company believes that it has access to capital resources through possible public or private equity offerings, or other means.

Industry Context

StockSavvy.ai notes that Myomo operates in the competitive medical device sector, specifically focusing on wearable robotics for neuromuscular disorders. The company's strategy to shift towards recurring revenue streams and reduce reliance on direct advertising aligns with industry trends favoring more sustainable customer acquisition models. The focus on Medicare and international markets highlights the global nature of medical device commercialization.

Comparison to Industry Standards

• The company's gross margin of 72.1% for Q2 2026 is strong, particularly for a medical device company, indicating efficient manufacturing and pricing power.
• However, the continued net loss and negative cash flow from operations are common for early-stage medical device companies investing heavily in R&D and market penetration, but sustained losses require careful monitoring.
• Competitors in the orthotics and prosthetics market include companies like Össur, Ottobock, and Hanger Clinic, though Myomo's focus on myoelectric upper limb braces is a more specialized niche.
• The company's reliance on Medicare reimbursement (51% of revenue for H1 2026) is a critical factor, as changes in government healthcare policy can significantly impact revenue, a common challenge for many medical device firms serving government-funded healthcare systems.

Legal Proceedings

• There are no material claims, assessments, or litigation against the Company as of June 30, 2026.

Stakeholder Impact

• Shareholders: Continued net losses and reliance on external financing may impact stock valuation and future dilution. However, revenue growth and margin improvement are positive indicators.
• Creditors: The company has a significant debt load, and compliance with covenants under the Loan and Security Agreement is crucial for maintaining access to liquidity.
• Employees: Stock-based compensation is a significant expense, indicating a reliance on equity incentives for employees.
• Customers: Continued product development and market expansion aim to improve access and functionality for patients with neuromuscular disorders.

Next Steps

• Expand the MyoConnect program to generate referrals in rehab clinics and stroke centers.
• Continue growth in revenues in the U.S. O&P channel and international operations.
• Reduce the cost of patient acquisition in the direct billing channel.
• Minimize the growth in fixed expenses.
• Potentially access additional capital through public or private equity offerings or other means if necessary.

Key Dates

Recommendation

The company shows positive revenue growth and improving gross margins, indicating operational progress. However, persistent net losses, significant derivative liability impacts, and reliance on external financing and reimbursement create substantial risk. While there are signs of recovery and strategic shifts, the path to profitability remains uncertain, warranting a hold position until sustained profitability and cash flow generation are demonstrated.

Keywords

MyoPro, orthotics, neuromuscular disorders, medical robotics, wearable technology, revenue growth, gross margin, Medicare reimbursement